يحاول ذهب - حر
Revamping multi-tier distribution: Ensuring consistent availability for India's pharma growth
March 2025
|Express Pharma
Chandrachur Datta, Partner, Vector Consulting Group explores how revamping the multi-tier distribution system with a demand-driven approach can optimise inventory, improve stockist efficiency, and ensure seamless access to medicines, benefiting pharma companies, stockists, and patients alike
India's pharma market is on a rapid growth trajectory, projected to reach $130 billion by 2030, driven by increasing affluence, improved health-care access and rising income levels. However, despite this significant opportunity, pharma companies struggle to ensure consistent product availability at chemists across the country.
The cost of inconsistent quality
A survey by Vector Consulting Group (n=934 chemists) revealed that even top pharma firms have only 60-85 per cent brand reach at chemists, leading to frequent prescription and substitutions.
This is despite companies carrying high inventory in supply chain to prevent this.
To address these issues, it's crucial to grasp the root cause, which create these inefficiencies. Understanding the intricacies of the multi-tier distribution system is the first step towards identifying and solving the problem.
Understanding the multi-tier distribution system
Pharma companies in India are typically structured into distinct therapeutic areas, each managed as a quasi-business unit with dedicated sales teams and tailored marketing strategies. Products from each division reach chemists through a network that includes company central/regional warehouses, carrying & forwarding agents (C&F), and stockists/sub-stockists. While central and regional warehouses and C&Fs may serve multiple divisions, the further distribution channels are customised to meet the specific needs and dynamics of each therapeutic segment. Additionally, each therapeutic division works with a unique set of stockists across the country. There may be some overlap, but not all stockists handle all therapeutic divisions, and not all divisions engage with every stockist. There are two kinds of stockists in India:
هذه القصة من طبعة March 2025 من Express Pharma.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Express Pharma
Express Pharma
Flexotherm Heating Tapes & Cords
Typical Applications of Heating Tapes and Cords in Industrial Solvent Handling
1 mins
October 2025
Express Pharma
DRIVING INDIA'S INNOVATION EDGE
Pharma leaders come together to highlight Bengaluru's R&D strength, tech ecosystem, and talent pool to power India Pharma Inc's shift from generics to innovation and global leadership
16 mins
October 2025
Express Pharma
Al compass: Transforming pharma commercialisation
As the world evolves at a rapid pace, pharma companies are embracing smarter approaches, leveraging Al across nearly every aspect of commercialisation, from market forecasting and personalised marketing to dynamic pricing and beyond. In this article, Neha Aathavale takes the pulse of the industry to explore who is taking note and how companies are beginning to put Al into action in their commercial operations
7 mins
October 2025
Express Pharma
PRIME NEO: New age doors from Gandhi Automation
Gandhi Automations presents the multi-composites, high-performance door PRIME NEO for clean environments. Complete Washable, Greater Sealing and Pressure Resistant.
1 mins
October 2025
Express Pharma
Unani Medicine: At crossroads of tradition and modernity
Manufacturers, academic institutions and research councils are working together to elevate Unani medicine through clinical validation and policy alignment with international standards, finds Swati Rana
7 mins
October 2025
Express Pharma
Single-Use Technologies in Biologics Manufacturing: Benefits, Challenges, and Growing Demand
The biopharmaceutical industry is increasingly adopting single-use technology (SUT) to achieve flexibility, cost efficiency, and faster time-to-market. Compared with stainless steel systems, SUT reduces capital investment, eliminates cleaning and sterilization steps, lowers contamination risk, and shortens production timelines.
1 min
October 2025
Express Pharma
Sustainable packaging with Romaco and Liveo Research
Recycable blister packs
3 mins
October 2025
Express Pharma
With India soon to be three times the population of the EU, it makes perfect sense to have manufacturing here
As part of Sweden's Focus Asia programme, a high-level SME delegation recently visited India to strengthen bilateral ties and explore collaborations across sectors including pharma, biotech and others. Building on the momentum of the \"Time for Sweden\" event, the visit underscored Sweden's commitment to innovation, sustainability, and co-creation with India. Among the delegation was Emil Alexander Byström, CEO of SpinChem AB, who in an interaction with Kalyani Sharma shared his insights on how advanced Swedish technologies like biocatalysis and the company's patented Rotating Bed Reactor (RBR) can accelerate India's pharma and biotech innovation journey while supporting sustainable growth.
3 mins
October 2025
Express Pharma
Cell therapy's next chapter: Industry embraces in-vivo innovation
Nikhil C Bhanumathi, Principal Clinical Lead, Thermo Fisher Scientific highlights that cell therapy is entering a bold new phase in 2025 as the industry shifts from complex, lab-based ex vivo CAR-T to faster, more accessible in vivo CAR-T innovations. This approach promises to expand access, lower costs, and potentially tackle solid tumors and autoimmune diseases
4 mins
October 2025
Express Pharma
Research misconduct ...can delay meaningful and reliable discoveries
Dr Gráinne McNamara, Research Integrity/Publication Ethics Manager, S. Karger AG explores how research misconduct, peer review fraud slow down pharma research. Of particular concern to India is the fact that India-based researchers constitute 5 per cent of articles in life sciences retracted between 1976-2023. India-based researchers also have one of the highest rates of retraction relative to the overall publication output. Over an email exchange with Viveka Roychowdhury, she details how publishers are now deploying AI tools, some of which contributed to the problem in the first place, to detect and avert fraudulent research submissions
6 mins
October 2025
Listen
Translate
Change font size

